All News

Comprehensive list of differential diagnosis of aortitis at vasculitis MOC session today. 1/3 of IgG4RD patients have vascular involvement (vasculitis+perivasc infiltrate) #ACR18 https://t.co/yu5ZO2dzCA
Didem Saygin, MD didemsayginmd ( View Tweet)
So proud of my dad for his hard work this year and his inspiring speech about the ACR's role in the future of medicine and politics! Also sincerely grateful for the opportunity to join in on so many of his trips and for always being so welcomed by the ACR. #ACR18 #Chicago https://t.co/fMQPLzMCcw
Clara Daikh CDaikh ( View Tweet)
In depth discussion on capillaroscopy by Dr. Cutolo. #ACR18 https://t.co/ni3HT94ue4
Lee Day UltrasoundRheum ( View Tweet)
Worth bearing in mind! #ACR18 https://t.co/07J8wj0j2C
Marco S Massarotti msmassarotti ( View Tweet)
1.Major political issues currently at stake for rheumatologists (eg CMS cuts for E/M service, step therapy) & need ⬆️ @ACRheum member help cc:@AngusWorthing 2.PEXIVAS: *negative* study on pheresis in severe AAV 3. Aggressive tx in MDA5+DM w/pred+CYC+tacro ⬆️survival #ACR18 https://t.co/TX6muMR3nO

Links:

Paul Sufka, MD psufka ( View Tweet)

My top 3 takehomes from #ACR18 are: @rheumnow 1. ACR is thinking about leaving ABIM & join ABAI to form a new board certifying body: ABAIR 2.Don’t worry too much about 5mg/kg/d HCQ dose- Dr M Petri still uses 6.5 mg/kg/d 3. No sig ⬆️ risk CV/DVT/PE with tofa and baricitib https://t.co/3YNhYltnfW

Links:

k dao KDAO2011 ( View Tweet)

#ACR18 @RheumNow abs 837 high dose flu vaccine in RA pts 2-3 times more likely to seroconvert vs standard dose. No increase in RA disease activity. ? translates to less flu?

Ian N Bruce Lupusdoc ( View Tweet)

#ACR18 @RheumNow abs 838 MDA5 pos DM-ILD. Hi dose steroids + tac + IV CycloP had 85%survival at 12m vs 33% in historic controls. Note 31%also had PEx. 90%had CMV reactivation. Impressive nevertheless. #RareDisease

Ian N Bruce Lupusdoc ( View Tweet)

Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

IgG4-related disease... almost completely unknown 10 years ago. "It is a perfect disease for rheumatologists to take care of." - Dr. John Stone #ACR18 @RheumNow

Brittany A MissbeeMD ( View Tweet)

IgG4-RD histopathology consistent across organs: lymphoplasmacytic infiltrate, obliterative phlebitis, storiform fibrosis. #ACR18 @RheumNow

Brittany A MissbeeMD ( View Tweet)

Pearls regarding IgG4-RD. Depressed complements commonly seen in renal involvement. #ACR18 @RheumNow https://t.co/m3oM4Aiuny
Brittany A MissbeeMD ( View Tweet)
#IgG4 RD is an indolent disease but can present with severe weight loss (>20 pounds), largely due to pancreatic destruction. #ACR18 @RheumNow

Brittany A MissbeeMD ( View Tweet)

Therapeutic potential of “glycoengineering" in autoimmune disease. Alter glycoforms of endogenous IgG -> reduce pathogenic impact of antibodies. Cell paper by Pagan JD et al https://t.co/UbBsE1jV4L Year in review basic science #ACR18 @RheumNow

Links:

D White WIRheum ( View Tweet)

TLR8 aberrantly expressed on pDCs (cells that make type-I IFN) in SSc patients Depletion ameliorates disease https://t.co/SmDdpIU2I1 Ah Kioon et al Year in review basic science #ACR18 @RheumNow

Links:

D White WIRheum ( View Tweet)

Stop by the ⁦@RheumResearch⁩ booth to get your ⁦@alhkim⁩ autographed flyers!!! #acr18 #rheumrockstars https://t.co/kVR4XB6ynO
Mary J. Wheatley MaryJWheatley ( View Tweet)
Anti-GBM positivity did not predict relapse in Goodpasture's (but ANCA did predict relapse in GBM disease) Abs 826, Cleveland Clinic Roundup - Cush, Kavanaugh #ACR18 @RheumNow

D White WIRheum ( View Tweet)

Toci in SSc failed to achieve primary endpoint (modified Rodman skin score) Abs 898 Roundup - Cush, Kavanaugh #ACR18 @RheumNow

D White WIRheum ( View Tweet)

Canabinoids in vitro CB2 receptor drives inflammation Set the stage for discovery/development of future antagonists? Danger of over-interpretation on the street Abs 1068 Roundup - Cush, Kavanaugh #ACR18 @RheumNow

D White WIRheum ( View Tweet)

MTX for OA of the knee 12 months, 155 pts, endpoint=pain statistically significant improvement, probably not clinically meaningful consistent with prior reports Abs 428 Roundup - Cush, Kavanaugh #ACR18 @RheumNow

D White WIRheum ( View Tweet)

×